BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study
Jan 30, 2023
- BiondVax’s preclinical proof-of-concept study was designed to mimic a real-world situation regarding at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare workers
- The study shows promising prophylactic results with hamsters receiving BiondVax’s inhaled NanoAb three hours before infection experiencing no significant weight loss over the six-day trial; follows previously reported data showing successful use of NanoAb as COVID-19 therapeutic
- First-in-human Phase 1/2a clinical trial is planned for later this year
Focused on the development, manufacture, and commercialization of innovative NanoAb immunotherapeutic products, BiondVax Pharmaceuticals (NASDAQ: BVXV) recently announced additional results in the company’s preclinical proof-of-concept study of its inhaled nanosized VHH-antibody (NanoAb) COVID-19 drug (https://ibn.fm/Kz8W4). BiondVax is developing a pipeline of innovative alpaca-derived NanoAb drugs addressing diseases with large underserved medical needs and attractive commercial opportunities, such as COVID-19, asthma, psoriasis, psoriatic arthritis, and macular degeneration. The research is being done as part of a collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen.
The study was designed to mimic a real-world situation in which at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare professionals may proactively protect themselves prior to…
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.
More News
X2, Troubled Six Flags Roller Coaster, to Close After Lawsuits
The ride at Magic Mountain near Los Angeles has fueled lawsuits claiming that it had caused brain injuries, including two that were fatal.
The volunteers baking birthday cakes for children
The Hampshire group says it has seen a rise in demand and it needs more volunteer bakers.
Regulating AI 'not the right place to start' says Bailey
AI needs "rigorous" testing and safeguards to contain risk, Andrew Bailey says.
DeepSeek and Huawei Target a Key Source of Nvidia’s A.I. Dominance
In China’s push for self-reliance in artificial intelligence, DeepSeek and Huawei have teamed up to develop software tools for advanced chips.
Greggs to cut 740 jobs and close factories
High street bakery brand Greggs has announced plans to shut four of its factories and cut 740 jobs.
Bracing for More Inflation Volatility
Consumers, business owners and investors are growing increasingly concerned about rising inflation, and its potential repercussions.
Africa's richest man launches Kenya oil refinery despite land protests
The Kenya refinery is part of Dangote's ambitious bid to expand and help industralise Africa by 2030.
Pie shop owner gets reply from Andy Burnham
Chorley businessman, Paul Bowen received a reply from Prime Minister Andy Burnham, after posting a video on social media about the closure of one of his shops due to the state of the high street.
Trump’s New Tariffs Face a Familiar Court Challenge
For the third time in less than two years, the Trump administration is set to return to court on Wednesday to defend its power to wage a punishing global trade war.
Trump’s New Tariffs Face a Familiar Court Challenge
For the third time in less than two years, the Trump administration is set to return to court on Wednesday to defend its power to wage a punishing global trade war.
How to Listen to Your Favorite Music, Online or Off the Grid
Streaming services can introduce you to a wonderland of nearly unlimited audio, but downloading your digital collection has advantages.
Doubters spur me on: why more women are taking up DIY
Female DIY experts and tradeswomen talk about their experiences of a traditionally male-dominated domain.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.